



Case report

There may be a link between intrahepatic cholestasis of pregnancy and familial combined hyperlipidaemia: a case report

Tosin Ajala¹, Junaid Rafi^{1*}, Richard Wray², Mark William Whitehead³ and Jamal Zaidi⁴

Addresses: ¹Department Obstetrics and Gynaecology, Basingstoke & North Hampshire NHS Trust, Aldermaston Road, Basingstoke, RG24 9NA, UK

²Department of Cardiology, Conquest Hospital, The Ridge St. Leonards on Sea, East Sussex, TN37 7RD, UK

³Department of Gastroenterology, Conquest Hospital, The Ridge St. Leonards on Sea, East Sussex, TN37 7RD, UK

⁴Department Obstetrics and Gynaecology, Conquest Hospital, The Ridge St. Leonards on Sea, East Sussex, TN37 7RD, UK

Email: TA - M4tosinajala@aol.com; JR* - drjunaidrafi@hotmail.com; RW - richard.wray@esht.nhs.uk; MWW - mark.whitehead@esht.nhs.uk; JZ - jamal.zaidi@esht.nhs.uk

* Corresponding author

Received: 18 July 2009 Accepted: 8 August 2009 Published: 17 September 2009

Cases Journal 2009, 2:8679 doi: 10.4076/1757-1626-2-8679

This article is available from: <http://casesjournal.com/casesjournal/article/view/8679>

© 2009 Ajala et al.; licensee Cases Network Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/3.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

A 26-year-old gravida 3 para 1+1 was referred for antenatal care. In her last pregnancy she had a early spontaneous preterm delivery at 32 weeks and 2 days complicated by intra hepatic cholestasis of pregnancy. She had a strong family history of ischemic heart and combined hyperlipidaemia. In view of her past obstetric history a baseline liver function test and fasting bile acid assay was carried out. Upto 21 week her Bile acids were normal but at 22 weeks her fasting bile acid assay increased to the upper limit of normal (9 µmol/L).

Ursodeoxycholic acid was started from 28 weeks gestation on a dosage of 500 mg b.i.d., which was subsequently increased to 500 mg t.d.s. at 32 weeks.

At 34 weeks she gave a history of occasional right upper quadrant abdominal pain and her biochemistry revealed raised serum aspartate transaminase ,alanine transaminase, fasting serum triglyceride and cholesterol levels 58 IU,79 IU/L,18.37 mmol/L and 25.7 mmol/L respectively. The triglyceride level was too high to calculate the low density lipoprotein cholesterol. A diagnosis of severe intrahepatic cholestasis of pregnancy in a patient with background familial combined hyperlipidaemia was made. Ultrasound abdomen and cardiotocography was normal. She had normal delivery. In cases of early onset cholestasis of pregnancy we suggest that lipid profiles are checked in these patients to rule out hyperlipidaemia and its attendant short term and long-term risks. More research will be required to ascertain if there is a link between these 2 disorders.

Introduction

We report a case of severe early onset reoccurring intrahepatic cholestasis of pregnancy (ICP) in a patient

with exacerbation of familial combined hyperlipidaemia (Fredrickson/WHO type V). To our knowledge this is the first described case.

Cholestasis of pregnancy is a rare disorder of unknown aetiology occurring in 1/1000-10,000 pregnancies [1]. It usually presents in the 3rd trimester of pregnancy and rarely in the second trimester before 25 weeks gestation. It characteristically presents as pruritus initially of the palms and soles mainly at night, progressively spreading to other parts of the body and increasingly becoming more persistent. The prevalence of jaundice varies from 17-75% [1-3]. While perinatal mortality can be as high as 20%, maternal monitoring of fetal movement and electronic fetal monitoring have been shown to be unreliable in preventing foetal loss [4].

Case presentation

A 26-year-old (Caucasian British, gravida 3 para 1+1) was referred to the Conquest Hospital, East Sussex at 8 weeks gestation for antenatal care.

She had suffered an early miscarriage at 9 weeks gestation with her first pregnancy and subsequently a spontaneous preterm delivery at 32 weeks and 2 days with her following pregnancy. That pregnancy had been complicated by intrahepatic cholestasis of pregnancy (ICP).

She had a strong family history of ischemic heart disease. On her maternal side, her grandfather had died of myocardial infarction (MI) at the age of 61 years and her uncle had an MI at the age of 45 years. On her paternal side of the family, her uncle aged 41 years, had suffered an acute coronary event. Her father aged 61 years, has combined hyperlipidaemia. She is a non-smoker.

At her booking visit at 10 weeks gestation clinical examination was unremarkable and her body mass index was normal. In view of her past obstetric history a baseline liver function test (LFT) and fasting bile acid assay (BA) was carried out. Her alanine transaminase (ALT) was slightly elevated 42 IU/L (3-31) otherwise her LFT and fasting BA assay were within normal limits, bile acid = 3 $\mu\text{mol/L}$ (Normal limits 0-10). At her next appointment (16 weeks gestation), she admitted to itching of her palms and soles mainly at night. A repeat LFT was all within normal limits as was the fasting BA, 6 $\mu\text{mol/L}$. She was again seen 2 weeks later in the antenatal clinic at 18 weeks gestation, her itching had worsened, and otherwise routine antenatal checks were normal. Her fasting BA assay remained normal 4 $\mu\text{mol/L}$, she was started on piriton tablets and calamine lotion and given a further appointment at 20 weeks at which her symptoms persisted and the fasting BA remained normal (6 $\mu\text{mol/L}$), as did her management.

Subsequent fetal anomaly scan carried out at 21 weeks gestation was normal.

At 22 weeks her fasting BA assay increased to the upper limit of normal (9 $\mu\text{mol/L}$), her LFT remained normal and in view of her persistent itching, it was recommended that she started ursodeoxycholic acid (UDCA), but this was declined. She continued on piriton tablets 4 mg 8 hourly. A follow-up appointment was arranged for 24 weeks, at this appointment she said that all was well, her latest fasting BA assay was 5 $\mu\text{mol/L}$.

However she admitted feeling unwell, experiencing some uterine contractions and reduced fetal movements at 26 weeks gestation. Routine examinations were normal. Ultrasound fetal biometric measurements were consistent with good growth and cardiotocography (CTG) tracing was reactive with evidence of fetal activity. LFT, urea and electrolytes were all within normal range. For the first time in this pregnancy her fasting BA assay was slightly above normal range (12 $\mu\text{mol/L}$). In view of her past obstetric history, she was given 2 doses of 12 mg of betamethasone intramuscular injections 24 hours apart. At 28 weeks gestation she admitted to worsen of her itching mainly at night, her fasting BA assay was 13 $\mu\text{mol/L}$ and her LFT remained normal. She was commenced on UDCA 500 mg twice daily orally, vitamin K 10 mg daily and aqueous menthol cream at night for relief of itching.

We decided to see her weekly for clinical review and monitoring of her biochemistry. Her symptoms remained unchanged over the following 3 weeks as did her biochemistry notably her fasting BA assay 7, 1 and 7 $\mu\text{mol/L}$ at 29, 30 and 31 weeks respectively.

Fetal growth ultrasound scan and CTG monitoring were reassuring.

At 32 weeks gestation, she complained of worsening pruritis, she noticed that her urine had become darker but denied change in the colour of her faeces. Her serum BA shot up to 161 $\mu\text{mol/L}$, while her LFT remained normal. The decision was made to increase the UDCA to 500 mg t.d.s.

At 34 weeks she gave a history of occasional right upper quadrant abdominal pain associated with vomiting described as "soap-like". On examination she was anicteric, normotensive with vague upper right abdominal tenderness. Her biochemistry revealed raised serum aspartate transaminase (AST) and ALT 58 and 79 IU/L respectively. The blood sample was grossly lipaemic; fasting serum triglyceride and cholesterol levels were significantly raised 18.37 mmol/L and 25.7 mmol/L respectively. The triglyceride level was too high to calculate the low density lipoprotein cholesterol (LDLC). Her serum amylase level was normal 17 IU/L as was her thyroid function test. Her fasting BA assay was raised; 134 $\mu\text{mol/L}$. Upper abdominal ultrasounds scan revealed a normal liver

Table 1. Postnatal lipid profile

Post-op (day)/ weeks	Cholesterol (mmol/L)	Triglyceride (mmol/L)
0	22.30	14.97
3	19.0	15.78
5	17.30	15.28
9	13.40	13.89
6 weeks	8.10	3.97

and pancreas with evidence of multiple gall bladder calculi. Fetal wellbeing was confirmed by reactive CTG and satisfactory growth on ultrasound scan.

A diagnosis of severe ICP in a patient with background familial combined hyperlipidaemia was made. We excluded acute fatty liver of pregnancy and closely observed her for the onset of superimposed acute pancreatitis in the presence of the hypertriglyceridaemia.

The patient was placed on reduced fat diet to less than 10%, increased fluid intake (3 Litres /24 hours), daily serum amylase and lipid monitoring. We planned to induce labour at 34 weeks and 3 days.

She presented at 34 weeks and 2 days in established labour and following a 7-hour labour had a spontaneous vaginal delivery of a live 2550 g male baby. Apgar scores were 5 @ 1 minute and 8 @5 minutes.

Her lipid profile was assessed on day 3, 5, 9 and 6 weeks postpartum (Table 1).

Discussion

Physiological hyperlipidaemia of pregnancy consist primarily of an increase in triglycerides, with a lesser degree of a rise in cholesterol and phospholipids in pregnancy [5]. This physiological change is exacerbated in cases with underlying familial hyperlipidaemia, with the attendant risk of cholesterol gall stone formation and acute pancreatitis secondary to the hypertriglyceridaemia.

Our patient presented with a known history of severe ICP and a strong family history of familial combined hyperlipidaemia. She had never been diagnosed with hyperlipidaemia prior to this pregnancy. This is probably explained by the absence of clinical features, such as tuberoeruptive xanthoma or hepatomegaly. Her previous preterm delivery at 32 weeks, a known complication of cholestasis of pregnancy [6], may have predated the excessive increase in serum level of triglycerides as to induce the lipaemic serum which aroused suspicion in this case.

While the aetiology of cholestasis of pregnancy remains unknown, studies of the pathogenesis indicate abnormalities in the metabolism of sex hormones and BA.

Clinical studies support an aetiological role of estrogens. These include the relationship between onset of disease and high levels of oestrogen in the third trimester, higher incidence of cholestasis of pregnancy in twin pregnancies and similar symptoms in postnatal patients that use the combined oral contraceptive pills for contraception [7]. Progesterone and BA metabolism in patients with cholestasis of pregnancy has been shown to differ from that of healthy patients. While the overall progesterone synthesis remains unchanged from that in normal pregnancies, patients with ICP have been shown to have a higher proportion of mono and disulfated metabolites of serum progesterone. Glucuronidated metabolites are however similar to that of healthy pregnant patients. This has led to the suggestion of a selective defect in the biliary excretion of sulphated progesterone metabolites into bile [8].

Cholesterol is essential in the production and integrity of the cell membrane; it is also the precursor for the synthesis of steroid hormones and BA. Exported cholesterol from the liver and intestines exceed peripheral catabolism, except during growth or tissue repair. The excess cholesterol is returned to the liver (reverse cholesterol transport process) and eliminated in bile as BAs and faecal sterols. This process of BA synthesis is one of the predominant means of excretion of excess cholesterol [9-10]. Up regulation of BA synthesis by lipoprotein cholesterol through increased cholesterol 7-alpha hydroxylase (the rate determining step for conversion of cholesterol to BAs) has been shown in in-vitro animal studies [11].

The role that the underlying familial combined hyperlipidaemia played in the severity of her ICP remains unclear. We suspect that while she probably had a genetic predisposition to ICP [7], her excessive circulating cholesterol could have been an aggravating factor.

UDCA, a hydrophilic BA was started from 28 weeks gestation on a dosage of 500 mg bd, which was subsequently increased to 500 mg tds at 32 weeks following a sudden steep rise in serum BA level to 161 $\mu\text{mol/L}$ and finally peaked at 207 $\mu\text{mol/L}$ at 34 weeks (Figure 1). While there have been some encouraging reports from some small studies, mainly in the improvement of BA levels and LFT, meta-analysis of the use of UDCA have failed to show significant benefits in the use of this medication for the persistent alleviation of pruritus [12].

In the presence of the patient's underlying hyperlipidaemia, early management with low fat diet would have improved her lipid state [13] reducing the attendant risk of acute intrapartum pancreatitis that is associated with a maternal mortality as high as 20%, which was a real concern in our case [14]. We also suggest that improved lipid profile may have improved our control of the ICP.




Figure 1. Trend of bile acids (umol/L) levels at different gestations. Ursodeoxycholic acid 500 mg bd from 28 weeks gestation, increased to tds from 32 weeks gestation.

Conclusion

In cases of early onset cholestasis of pregnancy we suggest that lipid profiles are checked in these patients to rule out hyperlipidaemia and its attendant short term and long-term risks. More research will be required to ascertain if there is a link between these 2 disorders.

Abbreviations

ALT, alanine transaminase; AST, aspartate transaminase; BA, Bile acids; CTG, cardiotocography; ICP, intrahepatic cholestasis of pregnancy; LDLC, low density lipoprotein cholesterol; LFT, liver function test; MI, myocardial infarction; UDCA, ursodeoxycholic acid.

Consent

Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal

Competing interests

The authors declare that they have no competing interests

Authors' contributions

TA and JR was the major contributor in writing. RW, MW and JZ were involved in management. They also analyzed and interpreted the patient data revised it critically for important clinical and educational content.

References

1. Reyes H: **Review: Intrahepatic cholestasis. A puzzling disorder of pregnancy.** *J Gastroenterol Hepatol* 1997, **12**:211-216.
2. Brites D, Rodrigues CM, Oliveira N, Cardoso M, Graça LM: **Correction of maternal serum BA profile during ursodeoxycholic acid therapy in cholestasis of pregnancy.** *J Hepatol* 1998, **28**:91-98.
3. Borum ML: **Hepatobiliary diseases in women.** *Med Clin North Am* 1998, **82**:51-75.
4. Riosco AJ, Ivankovic MB, Manzur A, Hamed F, Kato SR, Parer JT, Germain AM: **Intrahepatic cholestasis of pregnancy: A retrospective case-control study of perinatal outcome.** *Am J Obstet Gynecol* 1994, **170**:890-895.
5. Warth MR, Arky RA, Knopp RH: **Lipid metabolism in pregnancy. II. Altered lipid composition in the intermediate, very low,**

low and high-density lipoprotein fractions. *J Clin End & Metab* 1975, **41**:649-655.

6. Reid R, Ivey KJ, Rencoret RH, Storey B: **Fetal complications of obstetric cholestasis.** *Br Med J* 1976, **1**:807-872.
7. Germain AM, Nien JK, Mena B, Carvajal JA: **IRIS—International Registry of Intra-hepatic Cholestasis of Pregnancy-Related Stillbirth.** *Front in Fetal Health* 2001, **2**:1-6.
8. Reyes H, Sjøvall J: **BAs and progesterone metabolites in intrahepatic cholestasis of pregnancy.** *Ann Med* 2000, **32**:94-106.
9. Bjorkhem I: **Mechanism of bile acid biosynthesis in mammalian liver.** In *In Sterols and Bile Acids. New Comprehensive Biochemistry. Volume 12.* Edited by Danielsson H, Sjøvall J. Amsterdam: Elsevier; 1985:231-278.
10. Carey MC, Duane WC: **Enterohepatic circulation.** In *The liver. Biology and Pathobiology.* 3rd edition. Edited by Arias IM, Boyer JL, Fausto N, Jakoby WB, Schachter DA, Shafritz DA. New York: Raven; 1994:719-767.
11. Post SM, Twisk J, van der Fits L, de Wit EC, Hoekman MF, Mager WH, Princen HM: **Lipoprotein cholesterol uptake mediates up-regulation of BA synthesis by increasing cholesterol 7 alpha-hydroxylase but not sterol 27-hydroxylase gene expression in cultured rat hepatocytes.** *Biochem J* 1999, **341**:339-346.
12. Burrows RF, Clavisi O, Burrows E: **Interventions for treating cholestasis in pregnancy.** *Cochrane Database Syst Rev* 2001, **(4)**: CD000493.
13. Glueck CJ, Christopher C, Mishkel MA, Tsang RC, Mellies MJ: **Pancreatitis, familial hypertriglyceridaemia and pregnancy.** *Am J Obstet Gynecol* 1980, **136**:755.
14. Montgomery WH, Miller FG: **Pancreatitis and pregnancy.** *Obstet Gynecol* 1986, **35**:1054.

Do you have a case to share?

Submit your case report today

- Rapid peer review
- Fast publication
- PubMed indexing
- Inclusion in Cases Database

Any patient, any case, can teach us something



**CASES
NETWORK**

www.casesnetwork.com